[Hypocomplementemic urticarial vasculitis]

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Hypocomplementemic urticarial vasculitis (HUV), also known as anti-C1q vasculitis, is a rare systemic small vessel vasculitis of unknown cause.
• Key features include urticarial lesions, hypocomplementemia, and systemic involvement (musculoskeletal, ocular, GI, pulmonary, renal).

Purpose of the Study:

• To review the current understanding of Hypocomplementemic urticarial vasculitis (HUV).
• To summarize the limited published data on therapeutic management strategies for HUV.

Main Methods:

• Literature review of published data on HUV.
• Analysis of reported therapeutic interventions and outcomes.

Main Results:

• Low C1q levels appear more sensitive than anti-C1q antibodies for HUV diagnosis.
• Hydroxychloroquine and colchicine show promise as first-line treatments.
• For refractory cases, corticosteroids with immunosuppressants (azathioprine, mycophenolate mofetil, cyclophosphamide) or rituximab demonstrate efficacy.

Conclusions:

• The optimal treatment strategy for HUV remains undefined.
• Further research is needed to establish evidence-based guidelines for HUV management.